Ongentys
Named-patient access overview. Ongentys is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Ongentys (opicapone) is a once-daily, peripherally acting catechol-O-methyltransferase (COMT) inhibitor approved by the US Food and Drug Administration in April 2020 as adjunctive therapy to levodopa and carbidopa for the treatment of off episodes in patients with Parkinson's disease. Opicapone was approximately developed by Bial-Portela, a Portuguese pharmaceutical company, and is commercialised in the United States by Neurocrine Biosciences under license. The drug is supplied as a 50 mg oral capsule taken once daily at bedtime, with food avoidance for one hour before and after the dose.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Ongentys
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Ongentys is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Ongentys in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Ongentys
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.